Skip to main content

LLS IMPACT guidelines

Making an Impact on Clinical Trial Access

 

LLS seeks to bring clinical trials to the patients through the Influential Medicine Providing Access to Clinical Trials (IMPACT) program. The overall goal is to expand access to high-quality clinical trials to patients by having clinical trial participation occurring at local community oncology centers. These clinical trials will be hosted by major cancer centers who will partner with community-based oncologists to facilitate recruitment and participation of patients at community oncology centers. Though all patients at these community centers are welcome in IMPACT, this program provides the opportunity to increase the participation of patients who are traditionally unrepresented in clinical trials, including those who are rural, minority, and/or economically disadvantaged.


2021-2022 Application Key Dates

Phase Date
Call for Proposals September 2021
Letter of Intent Due December 15, 2021, 3:00 PM (ET)
Full Application Phase Deadline February 25, 2022, 3:00 PM (ET)
Notification of Awards June 2022
LLS' receipt of signed Grant Agreement and Milestones September 1, 2022
Funding Start Date October 1, 2022

 

General Application Instructions

The IMPACT application will be completed in two phases. Letter of Intent and Full Application.

Mission Score

During the review process, each application shall receive two Mission Scores (in addition to the Priority Scores), which reflect the purpose of the program within LLS’s overall Mission. 

Community center participation:

  • Mission Score 1: High likelihood of increasing participation of patients at community centers in clinical trials above 20% within the grant timeframe.
  • Mission Score 2: Moderate likelihood of increasing participation of patients at community centers in clinical trials above 20% within the grant timeframe.
  • Mission Score 3: Low likelihood of increasing participation of patients at community centers in clinical trials above 20% within the grant timeframe.

Underserved community participation:

  • Mission Score a: High likelihood of increasing the participation of underserved communities in the community center-associated clinical trials.
  • Mission Score b: Moderate likelihood of increasing the participation of underserved communities in the community center-associated clinical trials. 
  • Mission Score c: Low likelihood of increasing the participation of underserved communities in the community center-associated clinical trials. 

Missions Scores of 1, 2, a, and b are fundable. Mission Scores of 3 and c are not fundable.